Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 27;11:2040622320916014. doi: 10.1177/2040622320916014

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2020

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — Efficacy of short-term and low-dose IL-2 treatment in regulating levels of CD4⁺T subsets. (a, b, e, f) Absolute numbers of Th1, Th2 and the ratio of Th1/Th2 and Th17/Treg in PB were no statistical difference after IL-2 treatment. (c, d) Absolute numbers of Th17 and Treg cells in PB, especially Tregs, were significantly increased in patients after IL-2 treatment. Within-group comparisons were made using the Wilcoxon test before (blue) and after (red) IL-2 therapy.

IL-2, interleukin-2; PB, peripheral blood; Tregs, regulatory T cells.

**p < 0.01, ***p < 0.001. Asymptotic significances (2-sided tests) were displayed. The significance level was p < 0.05.